Browse the evidence

Higher intake of white rice (≥450g/d compared with <150g/d) is associated with an increased risk of diabetes (HR: 1.20; 95% CI: 1.03-1.41, p for trend=0.003).

Practitioners should consider advising moderation in white rice consumption to mitigate diabetes risk.

The highest risk of diabetes associated with white rice intake was observed in South Asia (HR: 1.65; 95% CI: 1.17-2.34, p for trend=0.02).

Healthcare providers in South Asia should be particularly aware of the risks associated with high white rice consumption.

Obesity is accompanied by significant health consequences, including increased incidence of heart disease, some types of cancers, and Type 2 diabetes.

Healthcare providers should consider these health risks when addressing obesity.

The marketing of sugar-sweetened beverages may contribute to global trends in calorie intake and obesity.

Marketers and public health officials should consider the impact of beverage marketing on obesity trends.

The intake of saturated fatty acids (SAFAs) is directly associated with coronary heart disease (CHD) mortality, with a hazard ratio of 1.28 for one standard deviation increase.

Practitioners should consider the impact of saturated fat intake on heart disease risk in middle-aged men.

The intake of mono-unsaturated fatty acids (MUFAs) is inversely associated with coronary heart disease (CHD) mortality, with a hazard ratio of 0.84 for one standard deviation increase.

Practitioners should encourage the intake of mono-unsaturated fats to potentially lower heart disease risk.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT may not be effective, some improvement in menstrual frequency can occur over time.

Tirzepatide is linked to a significantly reduced risk of overall hematologic malignancy (OR = 0.14, 95%CI = 0.03-0.60), particularly for lymphoma.

Tirzepatide may be a safer option for patients concerned about hematologic malignancies.

Semaglutide demonstrated an SAE incidence of 8.9%, compared to 6.2% for Liraglutide.

Practitioners should be aware of the SAE incidence when prescribing these medications.

Discontinuation rates due to adverse effects were 10.3% for Semaglutide and 8.3% for Liraglutide.

Practitioners should consider these discontinuation rates when evaluating treatment options.

49% of patients receiving semaglutide treatment had a full stomach compared to 18% of matched controls.

Clinicians should be aware of the increased risk of full stomach in patients on semaglutide during pre-operative assessments.

Chronic low-grade inflammation underlies psoriasis and hidradenitis suppurativa, which can worsen with obesity.

Weight management is crucial for patients with these skin diseases to prevent worsening of their conditions.

GLP-1a therapy was associated with a mean change in body mass index (BMI) of −0.83 kg/m2 in treated patients compared to −0.70 kg/m2 in those without GLP-1a therapy.

GLP-1a therapy may lead to modest reductions in BMI in a real-world setting.

In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs.

Practitioners should be aware that real-world outcomes may differ from clinical trial results.

81.5% of patients achieved excess weight loss (EWL) ≥50% and 51.1% achieved EWL ≥70% during follow-up.

Surgeons can expect a significant proportion of patients to achieve substantial weight loss post-surgery.

Laparoscopic Roux-en-Y gastric bypass (LRYGB) results in higher rates of sustained excess weight loss compared to laparoscopic sleeve gastrectomy (LSG).

LRYGB may be a more effective option for patients seeking long-term weight loss.

A greater proportion of AOM-naïve patients achieved ≥15% and ≥20% total body weight loss at 12 months compared to non-AOM-naïve patients.

Clinicians should note that AOM-naïve patients are more likely to achieve significant weight loss with semaglutide.

Obesity is a major public health problem with a prevalence increasing at an alarming rate worldwide.

Health practitioners should prioritize addressing obesity as a critical public health issue.

The effectiveness of currently approved anti-obesity drugs and other therapeutic avenues is reviewed.

Healthcare providers should stay informed about the effectiveness of anti-obesity medications.

Semaglutide improved hemoglobin A1c levels and reduced glycemic variability without increasing hypoglycemia.

Semaglutide may enhance glycemic control in type 1 diabetes patients.

Several agencies have approved tirzepatide for the treatment of type 2 diabetes and obesity.

Tirzepatide is a viable treatment option that is recognized by regulatory agencies for managing type 2 diabetes and obesity.

Obesity is the most powerful promoter of type 2 diabetes (T2DM) and increases the risk of many other metabolic and cardiovascular diseases.

Weight management is crucial for preventing and treating T2DM.

Tirzepatide has potential cardiovascular benefits.

Practitioners should consider the cardiovascular implications when prescribing TZP.

Brown adipose tissue (BAT) is identified as a thermogenic organ in human adults, which may be targeted for obesity and cardiometabolic disease treatment.

Activating BAT could be a novel strategy for treating obesity and related diseases.